Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma

Journal of Clinical Oncology

Volumn 17, Issue 8, 1999, Pages 2530-2540

  Motzer, Robert J ^a   Mazumdar, Madhu ^a   Bacik, Jennifer ^a   Berg, William ^a   Amsterdam, Alison ^a   Ferrara, Joseph ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMINOPTERIN; ANTINEOPLASTIC AGENT; DIDEMNIN A; DOXORUBICIN; ELLIPTINIUM; FLUTAMIDE; HEMOGLOBIN; INTERLEUKIN 2; LACTATE DEHYDROGENASE; N METHYLFORMAMIDE; RETINOIC ACID; SURAMIN; TOPOTECAN; TRIMETREXATE; VINBLASTINE; VINDESINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STATISTICAL MODEL;

EID: 0032772880     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.8.2530     Document Type: Article

References (50)

1. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 335:865-875, 1996
2. Motzer RJ, Russo P, Nanus DM, et al: Current Problems in Cancer: Renal Cell Carcinoma. St Louis, MO, Mosby, 1997, pp 189-232
3. Motzer RJ, Vogelzang NJ: Chemotherapy for renal cell carcinoma, in Raghaven D, Scher HI, Leibel SA, et al (eds): Principles and Practice of Genitourinary Oncology. Philadelphia, PA, Lippmcott-Raven, 1997, pp 885-896
4. Rosenberg SA, Lotze MT, Muul LA, et al: A progress report of the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889-897, 1987
5. Wirth MP: Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 20:283-295, 1993
6. Vogelzang NJ, Lipton A, Figlin RA: Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: An outpatient multicenter trial. J Clin Oncol 11:1809-1816, 1993
7. Elson PJ, Witte RS, Trump DL: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48:7310-7313, 1988
8. De Forges A, Rey A, Klink M, et al: Prognostic factors of adult metastatic renal cell carcinoma: A multivariate analysis. Semin Surg Oncol 4:149-154, 1988
9. Palmer PA, Vinke J, Philip T, et al: Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 3:475-480, 1992
10. Jones M, Selby P, Franks C, et al: The impact of interleukin-2 on survival in renal cancer: A multivariate analysis. Cancer Biother 8:275-288, 1993
11. Hanninen EJ, Kirchner H, Atzpodien J: Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive patients. J Urol 155:19-25, 1996
12. Fossa SD, Kramer A, Droz JP: Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 30A:1310-1314, 1994 (suppl)
13. Minasian LM, Motzer RJ, Gluck L, et al: Interferon alfa-2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11:1368-1375, 1993
14. Wong PP, Yagoda A, Currie VE, et al: Phase II study of vindesine sulfate in the therapy for advanced renal carcinoma. Cancer Treat Rep 61:1727-1729, 1977
15. Zeffren J, Yagoda A, Watson RC, et al: Phase II trial of methyl-GAG in advanced renal cancer. Cancer Treat Rep 65:525-527, 1981
16. Ahmed T, Benedetto P, Yagoda A, et al: Estrogen, progesterone, and androgen-binding sites in renal cell carcinoma: Observations obtained in phase II trial of flutamide. Cancer 54:477-481, 1984
17. Benedetto P, Ahmed T, Needles B, et al: Phase II trial of 4′epi-adriamycin for advanced hypernephroma. Am J Clin Oncol 6:553-554, 1983
18. Scher HI, Yagoda A, Ahmed T, et al: Phase II trial of 10-deazaaminopterin for advanced hypernephroma. Anticancer Res 4:409-410, 1984
19. Scher HI, Schwartz S, Yagoda A, et al: Phase II trial of bisantrene for advanced hypernephroma. Cancer Treat Rep 66:1653-1655, 1982
20. Scher HI, Yagoda A, Ahmed T, et al: Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma. Cancer Chemother Pharmacol 14:79-80, 1985
21. Sternberg CN, Yagoda A, Scher HI, et al: Phase II trial of N-methylformamide for advanced renal cell carcinoma. Cancer Treat Rep 70:681-682, 1986
22. Sternberg CN, Yagoda A, Casper E, et al: Phase II trial of elliptinium in advanced renal cell carcinoma and carcinoma of the breast. Anticancer Res 5:415-417, 1985
23. Sternberg CN, Yagoda A, Scher H, et al: Phase II trial of trimetrexate in patients with advanced renal cell carcinoma: Clinical Community Oncology Program. Eur J Cancer Clin Oncol 25:753-754, 1989
24. Law TM, Motzer RJ, Mazumdar M, et al: Phase III randomized trial of interleukin-2 with or without lymphine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76:824-832, 1995
25. Motzer RJ, Schwartz L, Law TM, et al: Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: Antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 13:1950-1957, 1995
26. Motzer RJ, Scher H, Bajorin D, et al: Phase II trial of Didemnin B in patients with advanced renal cell carcinoma. Invest New Drugs 8:391-392, 1990
27. Ilson DH, Motzer RJ, Kradin RL, et al: A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma. J Clin Oncol 10:1124-1130, 1992
28. Motzer RJ, Nanus DM, O'Moore P, et al: Phase II trial of suramin in patients with advanced renal cell carcinoma: Treatment results, pharmacokinetics, and tumor growth factor expression. Cancer Res 52:5775-5779, 1992
29. Motzer RJ, Lyn P, Fischer P, et al: Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 13:1958-1965, 1995
30. Law TM, Ilson DH, Motzer RJ: Phase II trial of topotecan in patients with advanced renal cell carcinoma. Invest New Drugs 12:143-145, 1994
31. Law TM, Mencel P, Motzer RJ: Phase II trial of hposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. Invest New Drugs 12:323-325, 1994
32. Motzer RJ, Murphy BA, Mazumdar M, et al: Randomized phase III trial of interferon alfa-2a (IFN) versus IFN plus 13-cis-retinoic acid (CRA) in patients (pts) with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 18:330a, 1999 (abstr 1271)
33. Berg WJ, Schwartz LH, Amsterdam A, et al: A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Invest New Drugs 15:353-355, 1997
34. Law TM, Motzer RJ, Minasian LM, et al: Risk stratification in advanced renal cell carcinoma: A single institution study of 237 patients. Proc Am Soc Clin Oncol 13:243, 1994 (abstr)
35. Orrell DH: Albumin as an aid to the interpretation of serum calcium. Clin Chim Acta 35:483-489, 1971
36. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
37. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
38. Cox DR, Oakes D: Analysis of Survival Data. New York, Chapman and Hall, 1990
39. Gentlemen R, Crowley J: Graphical methods for censored data. J Am Stat Assoc 86:678-683, 1991
40. Heller G, Simonoff JS: Prediction in censored survival data: A comparison of the proportional hazards and linear regression models. Biometrics 48:101-115, 1992
41. Collet D: Modelling Survival Data in Medical Research. London, UK, Chapman and Hall, 1994
42. Mazumdar M, Glassman J: Categorizing a prognostic variable: Review of methods, codes for easy implementation and application to decision-making about cancer treatments. Stat in Med (in press)
43. Chen CH, George SL: The bootstrap and identification of prognostic factor's via Cox's proportional hazards regression model. Stat Med 4:39-46, 1985
44. Sauerbrei W, Schumacher M: A bootstrap resampling procedure for model building: Application to the Cox regression model. Stat Med 11:2093-2109, 1992
45. Golimbu M, Joshi P, Sperber A: Renal cell carcinoma: Survival and prognostic factors. Urology 27:291-301, 1991
46. Maldazys JD, deKernion JB: Prognostic factors in renal cell carcinoma. J Urol 136:376-379, 1986
47. Thrasher JB, Paulson DF: Prognostic factors in renal cancer. Urol Clin North Am 20:247-261, 1993
48. Fossa S, Jones M, Joffe J, et al: Interferon-alpha and survival in renal cell cancer. Ann Oncol 76:286-290, 1995
49. Negrier S, Escudier B, Lasset C, et al: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338:1273-1278, 1998
50. Neves RJ, Zincke H, Taylor WF: Metastatic renal cell cancer and radical nephrectomy: Identification of prognostic factor and patient survival. J Urol 139:1173-1176, 1988